67Cu-SARTATE™ Peptide Receptor Radionuclide Therapy Administered to Pediatric Patients With High-Risk, Relapsed, Refractory Neuroblastoma

• ClinicalTrials.gov Identifier: NCT04023331
• Recruitment Status: Recruiting
• First Posted: July 17, 2019
• Last Update Posted: May 26, 2023
• Sponsor: Clarity Pharmaceuticals Ltd
• Information provided by (Responsible Party): Clarity Pharmaceuticals Ltd

Study Description

Brief Summary:

The aim of this study is to evaluate the safety and efficacy of 67Cu-SARTATE in pediatric patients with high-risk neuroblastoma.

Condition or disease	Intervention/treatment	Phase
Neuroblastoma; Relapsed Neuroblastoma; Refractory Neuroblastoma	Drug: 67Cu-SARTATE; Drug: 64Cu-SARTATE	Phase 1; Phase 2

Detailed Description:

This is an 'adaptive trial'. The trial design uses the accumulating data from the ongoing trial to modify aspects of the trial (e.g. dose, number of treatments). The trial is also a 'personalised trial' as the interval between treatments and number of treatments is determined for each patient individually.

This study is to be conducted in 2 phases, a dose escalation phase and a cohort expansion phase.

Dose escalation will be completed using a modified 3+3 study design with up to 4 Cohorts of increasing doses in MBq/kg. Pre-defined Dose Limiting Toxicities will be monitored for 6 weeks post administration of 1 therapy cycle of 67Cu-SARTATE.

Participants who demonstrate therapeutic benefit (defined as non progression as assessed by the Investigator using the International Neuroblastoma Response Criteria (INRC) guidelines) may be offered additional Therapy Cycles (each participant may receive a maximum of 4 Therapy Cycles in total).

Cohort expansion will commence once either the Maximum Tolerated Dose (MTD) for a single administration of 67Cu-SARTATE is established, or Cohort 4 has been completed. The study will be expanded to enroll an additional 10 subjects who will receive at least 2 therapy cycles of 67Cu-SARTATE at the MTD dose level. Participants who demonstrate therapeutic benefit (defined as non progression as assessed by the Investigator using the INRC guidelines) may be offered additional Therapy Cycles (each participant may receive a maximum of 4 Therapy Cycles in total).

The study also includes a long-term follow-up period to 36 months following the first dose of 67Cu-SARTATE, although in person study visits are not required.

Study Design

• Study Type: Interventional (Clinical Trial)
• Estimated Enrollment: 34 participants
• Allocation: N/A
• Intervention Model: Single Group Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: 67Cu-SARTATE™ Peptide Receptor Radionuclide Therapy Administered to Pediatric Patients With High-Risk Neuroblastoma: A Multi-center, Dose-escalation, Open-label, Non-randomized, Phase 1-2a Theranostic Clinical Trial
• Actual Study Start Date: August 18, 2020
• Estimated Primary Completion Date: December 2028
• Estimated Study Completion Date: December 2028

Arms and Interventions

Arm

Intervention/treatment

Experimental: 67Cu-SARTATE; 64Cu-SARTATE - patients will receive a bolus injection of 64Cu-SARTATE during screening, and following each 67Cu-SARTATE Therapy Cycle at a rate of 2.0 MBq/kg. 67Cu-SARTATE - In the dose escalation phase, patients will receive a single administration of 67Cu-SARTATE as an IV infusion (dose will be determined based on cohort allocation). In the expansion phase, patients will receive at least 2 administrations of 67Cu-SARTATE a the MTD level as a slow IV infusion. Participants in either phase of the study that demonstrate therapeutic benefit following treatment with 67Cu-SARTATE at any dose may be offered additional Therapy Cycles (each participant may receive a maximum of 4 Therapy Cycles in total).

Drug: 67Cu-SARTATE; 67Cu-labelled MeCOSar-Tyr3-octreotate; Other Name: Cu-67 SARTATE, copper 67 SARTATE; Drug: 64Cu-SARTATE; 64Cu-labelled MeCOSar-Tyr3-octreotate; Other Name: Cu-64 SARTATE, copper 64 SARTATE

Outcome Measures

Primary Outcome Measures :

1. Maximum Tolerated Dose (MTD) of 67Cu-SARTATE [ Time Frame: 6 weeks ]
   MDT as determined by cohort observations of Dose Limiting Toxicities
2. Safety and tolerability of Cu-67 SARTATE using Common Terminology Criteria for Adverse Events (CTCAE) [ Time Frame: Up to 36 months ]
   Safety will be assessed via vital signs, pathology tests (hematology, biochemistry, urinalysis, coagulation), physical examinations, electrocardiograms (ECGs) and spontaneous adverse event (AE) reporting.
3. Safety and tolerability of Cu-64 SARTATE using CTCAE [ Time Frame: Up to 36 months ]
   Safety will be assessed via vital signs, pathology tests (hematology, biochemistry, urinalysis, coagulation), physical examinations, ECGs and spontaneous AE reporting.
4. Overall response rate [ Time Frame: Up to 12 months ]
   As assessed by international neuroblastoma response criteria (INRC).
5. Best response [ Time Frame: 6 to 8 weeks post final therapy ]
   As assessed by international neuroblastoma response criteria (INRC).

Eligibility Criteria

• Ages Eligible for Study: Child, Adult, Older Adult
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

1. Participant is able and willing to provide informed consent (≥18 years), or informed consent is obtained by the parent or legal guardian for minor participants, with the minor providing age appropriate assent, according to local law and regulations;
2. Life expectancy ≥ 12 weeks;
3. Known high-risk neuroblastoma OR previously intermediate-risk neuroblastoma that has relapsed or progressed to high-risk, with failure to achieve complete response with standard therapy (defined as at least 4 cycles of aggressive multi-drug induction chemotherapy with or without radiation and surgery, or according to a standard high-risk treatment/neuroblastoma protocol), OR who are medically ineligible to receive standard treatment OR who are intolerant to standard treatment;
4. Adequate recovery from acute toxic effects of any prior therapy, as deemed by the Investigator or treating Sub-Investigator;
5. Adequate liver function as defined by the following laboratory values obtained within 28 days prior to administration of 64Cu-SARTATE: Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 3.0 x upper limit of normal (ULN);
6. Adequate renal function;
7. Adequate laboratory parameters: Absolute neutrophil count > 1.0 x 10 9/L; Platelet count > 50 x 10 9/L; Total bilirubin <1.5 x ULN;
8. Karnofsky or Lansky performance status ≥50;
9. All participants must have a hematopoietic stem cell product available (minimum CD34+ cell dose is ≥2 x 10 6 cells/kg);
10. Sexually active participants of reproductive potential must practice an effective method of birth control while participating on this study, to avoid possible damage to the fetus. Abstinence is considered acceptable;
11. 64Cu-SARTATE uptake on the 4 hour scan (SUVmax) of any lesion equal to or higher than that of the liver in order to move on to the therapy phase of the study.

Exclusion Criteria:

1. Participants with disease of any major organ system that would compromise their ability to tolerate therapy, as deemed by the Investigator or treating Sub-Investigator;
2. Any other active malignancy, or a history of prior malignancy within the past 3 years;
3. History of cardiac failure as evidenced by: dyspnea at rest, exercise intolerance, oxygen requirement, clinically significant cardiac dysfunction;
4. Planned administration of chemotherapy, anti-cancer cytokine therapy, immunotherapy or radiotherapy within 2 weeks prior to the administration of 64Cu-SARTATE;
5. Administration of therapeutic dose of 131I-MIBG within 8 weeks prior to the administration of 64Cu-SARTATE;
6. External beam radiation therapy (EBRT) to both kidneys or a single functioning kidney within 12 months prior to the administration of 64Cu-SARTATE;
7. Administration of any investigational agents within 21 days prior to administration of 64Cu-SARTATE;
8. Treatment with long acting somatostatin analogues (administered within 28 days prior to the administration of 64Cu-SARTATE), or short acting somatostatin analogues (administered within 24 hours prior to the administration of 64Cu-SARTATE);
9. Known sensitivity or allergy to somatostatin analogues;
10. Previous peptide receptor radionuclide therapy (PRRT);
11. Female participants who are pregnant or lactating;
12. Participants who are on hemodialysis;
13. QTc interval ≥ 0.45 seconds as measured by Screening ECG;
14. Participants with uncontrolled infection(s);
15. Any medical condition which the Investigator feels may interfere with the procedures or evaluations of the study;
16. Participants 12 months and younger will be excluded from cohorts where the planned single or cumulative administered activity is modelled to deliver a radiation dose to the marrow that exceeds 2 Gy.

Contacts and Locations

Contacts

Contact: Clarity Pharmaceuticals; +61 (0) 2 9209 4037; clinicaltrials@claritypharmaceuticals.com

Locations

United States, Arizona

Phoenix Children's Hospital; Recruiting

Phoenix, Arizona, United States, 85016

Principal Investigator: Francis Eshun, MD

United States, Missouri

Washington University School of Medicine; Recruiting

Saint Louis, Missouri, United States, 63110

Principal Investigator: Frederick Huang, MD

United States, New York

Memorial Sloan Kettering Cancer Center; Recruiting

New York, New York, United States, 10065

Principal Investigator: Neeta Pandit-Taskar, MD

United States, North Carolina

Atrium Health/ Levine Children's Hospital; Not yet recruiting

Charlotte, North Carolina, United States, 28203

Principal Investigator: Giselle Sholler, MD

United States, Ohio

Cincinnati Children's Hospital Medical Centre; Recruiting

Cincinnati, Ohio, United States, 45229

Principal Investigator: Brian Weiss, MD

United States, South Carolina

Medical University of South Carolina; Recruiting

Charleston, South Carolina, United States, 29425

Principal Investigator: Jacquline Kraveka, MD

United States, Texas

University of Texas Southwestern Medical Centre; Recruiting

Dallas, Texas, United States, 75390

Principal Investigator: Tanya Watt, MD

MD Anderson Cancer Center; Not yet recruiting

Houston, Texas, United States, 77030

Principal Investigator: Douglas Harrison, MD

United States, Wisconsin

University of Wisconsin; Recruiting

Madison, Wisconsin, United States, 53792

Principal Investigator: Kenneth DeSantes, MD

Sponsors and Collaborators

Clarity Pharmaceuticals Ltd

More Information

• Responsible Party: Clarity Pharmaceuticals Ltd
• ClinicalTrials.gov Identifier: NCT04023331
• Other Study ID Numbers: CL04
• First Posted: July 17, 2019
• Last Update Posted: May 26, 2023
• Last Verified: March 2023

• Studies a U.S. FDA-regulated Drug Product: Yes
• Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:

Neuroblastoma; Neuroectodermal Tumors, Primitive, Peripheral; Neuroectodermal Tumors, Primitive; Neoplasms, Neuroepithelial; Neuroectodermal Tumors; Neoplasms, Germ Cell and Embryonal; Neoplasms by Histologic Type; Neoplasms; Neoplasms, Glandular and Epithelial; Neoplasms, Nerve Tissue; Copper; Trace Elements; Micronutrients; Physiological Effects of Drugs